PE20001232A1 - QUINOLINE-DERIVED COMPOUNDS AND THEIR THERAPEUTIC USE - Google Patents

QUINOLINE-DERIVED COMPOUNDS AND THEIR THERAPEUTIC USE

Info

Publication number
PE20001232A1
PE20001232A1 PE1999001102A PE00110299A PE20001232A1 PE 20001232 A1 PE20001232 A1 PE 20001232A1 PE 1999001102 A PE1999001102 A PE 1999001102A PE 00110299 A PE00110299 A PE 00110299A PE 20001232 A1 PE20001232 A1 PE 20001232A1
Authority
PE
Peru
Prior art keywords
acid amide
carboxyl acid
trifluoromethylquinoline
quinoline
oxypyridin
Prior art date
Application number
PE1999001102A
Other languages
Spanish (es)
Inventor
John Gary Montana
Hazel Joan Dyke
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of PE20001232A1 publication Critical patent/PE20001232A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINOLINA DE FORMULA I, DONDE R1 ES CH3, CH2F, CHF2, CF3; R2 ES CH3, CF3; R3 ES F, Cl, Br, CN, CH3; R4 ES H, F, Cl, Br, CN, CH3. SON COMPUESTOS PREFERIDOS: (3-CLORO-1-OXIPIRIDIN-4-IL)AMIDA DE ACIDO 8-DIFLUOROMETOXI-2-METILQUINOLINA-5-CARBOXILICO; (3-CLORO-1-OXIPIRIDIN-4-IL) AMIDA DE ACIDO 8-DIFLUOROMETOXI-2-TRIFLUOROMETILQUINOLINA-5-CARBOXILICO; (3-CLORO-1-OXIPIRIDIN-4-IL)AMIDA DE ACIDO 8-METOXI-2-TRIFLUOROMETILQUINOLINA-5-CARBOXILICO; (3,5-DIFLUORO-1-OXIPIRIDIN-4-IL)AMIDA DE ACIDO 8-METOXI-2-TRIFLUOROMETILQUINOLINA-5-CARBOXILICO; (3,5-DICLORO-1-OXIPIRIDIN-4-IL)AMIDA DE ACIDO 8-METOXI-2-TRIFLUOROMETILQUINOLINA-5-CARBOXILICO; ENTRE OTROS. LOS COMPUESTOS DERIVADOS DE QUINOLINA INHIBEN LA FOSFODIESTERASA IV (PDE IV) O FACTOR DE NECROSIS TUMORAL POR LO QUE PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES ALERGICAS, INMUNES, INFLAMATORIAS COMO ASMA BRONQUITIS CRONICA, DERMATITIS ATOPICA, URTICARIA, ENFERMEDAD INFLAMATORIA PULMONAR CRONICA, ENFERMEDAD OBSTRUCTIVA DE LAS VIAS AEREAS, URTICARIA, CONJUNTIVITIS ALERGICA, INFLAMACION DEL OJOREFERS TO QUINOLINE DERIVATIVE COMPOUNDS OF FORMULA I, WHERE R1 IS CH3, CH2F, CHF2, CF3; R2 IS CH3, CF3; R3 IS F, Cl, Br, CN, CH3; R4 IS H, F, Cl, Br, CN, CH3. PREFERRED COMPOUNDS ARE: (3-CHLORO-1-OXIPYRIDIN-4-IL) 8-DIFLUOROMETOXY-2-METHYLQUINOLINE-5-CARBOXYL ACID AMIDE; (3-CHLORO-1-OXYPYRIDIN-4-IL) 8-DIFLUOROMETOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYL ACID AMIDE; (3-CHLORO-1-OXYPYRIDIN-4-IL) 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYL ACID AMIDE; (3,5-DIFLUORO-1-OXIPYRIDIN-4-IL) 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYL ACID AMIDE; (3,5-DICHLORO-1-OXYPYRIDIN-4-IL) 8-METOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYL ACID AMIDE; AMONG OTHERS. THE COMPOUNDS DERIVED FROM QUINOLINE INHIBIT PHOSPHODIESTERASE IV (PDE IV) OR TUMOR NECROSIS FACTOR SO THEY MAY BE USEFUL FOR THE TREATMENT OF ALLERGIC, IMMUNE, INFLAMMATORY DISEASES SUCH AS ASTHMA, CRYSTAL BRONCHITIS, ATHLETIC URTICAL, CRYSTAL BRONCHITIS, ATTACHED URINARY RADMA OBSTRUCTIVE AIRWAY, URTICARIA, ALLERGIC CONJUNTIVITIS, INFLAMMATION OF THE EYE

PE1999001102A 1998-11-04 1999-11-03 QUINOLINE-DERIVED COMPOUNDS AND THEIR THERAPEUTIC USE PE20001232A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824160.7A GB9824160D0 (en) 1998-11-04 1998-11-04 Heterocyclic compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
PE20001232A1 true PE20001232A1 (en) 2000-11-28

Family

ID=10841838

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001102A PE20001232A1 (en) 1998-11-04 1999-11-03 QUINOLINE-DERIVED COMPOUNDS AND THEIR THERAPEUTIC USE

Country Status (22)

Country Link
EP (1) EP1045845A1 (en)
JP (1) JP2002528541A (en)
KR (1) KR20010033842A (en)
CN (1) CN1287555A (en)
AR (1) AR021094A1 (en)
AU (1) AU735574B2 (en)
BR (1) BR9906719A (en)
CA (1) CA2312430A1 (en)
CO (1) CO5160316A1 (en)
GB (1) GB9824160D0 (en)
HU (1) HUP0100570A3 (en)
IL (1) IL136398A0 (en)
NO (1) NO20003439D0 (en)
NZ (1) NZ504933A (en)
PE (1) PE20001232A1 (en)
PL (1) PL341732A1 (en)
RU (1) RU2205830C2 (en)
SK (1) SK10082000A3 (en)
TR (1) TR200001941T1 (en)
TW (1) TW546296B (en)
WO (1) WO2000026208A1 (en)
ZA (1) ZA200002604B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
DE10318610A1 (en) * 2003-04-24 2004-11-11 Elbion Ag 7-azaindoles and their use as therapeutic agents
JP2007505834A (en) * 2003-09-15 2007-03-15 シェーリング　コーポレイション Synthesis of quinoline 5-carboxamides useful for the preparation of PDEIV inhibitors
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL329922A1 (en) * 1996-05-20 1999-04-26 Darwin Discovery Ltd Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
JP4373497B2 (en) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド Substituted azabicyclo compounds and their use as inhibitors of TNF and cyclic AMP phosphodiesterase production

Also Published As

Publication number Publication date
IL136398A0 (en) 2001-06-14
SK10082000A3 (en) 2001-01-18
GB9824160D0 (en) 1998-12-30
NO20003439L (en) 2000-07-03
NZ504933A (en) 2001-10-26
AU735574B2 (en) 2001-07-12
BR9906719A (en) 2000-10-17
AR021094A1 (en) 2002-06-12
EP1045845A1 (en) 2000-10-25
PL341732A1 (en) 2001-05-07
JP2002528541A (en) 2002-09-03
CO5160316A1 (en) 2002-05-30
AU1057100A (en) 2000-05-22
WO2000026208A1 (en) 2000-05-11
RU2205830C2 (en) 2003-06-10
CA2312430A1 (en) 2000-05-11
TW546296B (en) 2003-08-11
TR200001941T1 (en) 2001-01-22
HUP0100570A2 (en) 2001-10-28
CN1287555A (en) 2001-03-14
NO20003439D0 (en) 2000-07-03
HUP0100570A3 (en) 2002-12-28
ZA200002604B (en) 2001-05-28
KR20010033842A (en) 2001-04-25

Similar Documents

Publication Publication Date Title
ES2378881T3 (en) Naphthalene derivatives
AU2001236856B2 (en) Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
FI64159C (en) ORGANIC FRAGMENTATION EFFECTIVE ANTI-ALLERGIC 11-OXO-11-H-PYRIDO (2,1-B) -KINAZOLINE
ME01310B (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
BRPI0408369A (en) indole derivatives useful for treating disease
CR8649A (en) FORMAMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES
PE20060630A1 (en) SUBSTITUTE AMIDES OF HAVE-PYRROLCARBOXYLIC ACID, AMIDES OF PYRROLOTIAZOL-CARBOXYL ACID AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE IE
UY28339A1 (en) USED 2-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES
BR0206435A (en) Compound, pharmaceutical composition, methods of treating angiogenesis in a patient, treating kdr and proliferative-related disorders in a mammal, use of a compound, and process for preparing compounds
PE20080970A1 (en) DERIVATIVES OF 5-SUBSTITUTED QUINAZOLINONE AND COMPOSITIONS THAT INCLUDE THEM AND METHODS OF USING THEM
EA200400595A1 (en) BENZIMIDAZOLY, USED AS PROTEKINKINASE INHIBITORS
MX9405132A (en) TETRAHIDRO PIRAZOLOPIRIDINAS BICICLICAS.
ECSP056164A (en) USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES
FI945555A0 (en) Substituted oxindoles
UY28343A1 (en) USED 2-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES
PA8627001A1 (en) COMPOUNDS FOR THE TREATMENT OF DISEASES
RU2006146632A (en) CHINAZOLINONE DERIVATIVES USEFUL AS VANILOID ANTAGONISTS
PE20050480A1 (en) [2- (8,9-DIOXO-2,6-DIAZABICYCLO [5.2.0] NON-1 (7) -EN-2-IL) ALKYL] PHOSPHONIC ACID AND DERIVATIVES
JP5819188B2 (en) N-acylthiourea and N-acylurea inhibitors of hedgehog protein signaling pathway
Zabeer et al. Synthesis and bronchodilator activity of new quinazolin derivative
PE20001232A1 (en) QUINOLINE-DERIVED COMPOUNDS AND THEIR THERAPEUTIC USE
LeMahieu et al. (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents
ATE90348T1 (en) PYRIDO(2,3-D>PYRIMIDIN DERIVATIVES.
EP0376223A3 (en) Azaazulene derivative, process for preparing the same, and antiallergic agent and antiinflammatory agent containing the same
MXPA04003278A (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists.

Legal Events

Date Code Title Description
FC Refusal